Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. To determine the highest safe dose, subjects will receive different amounts of the drug. The first group of subjects will receive the lowest dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20 subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184 in this population.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Exelixis

Criteria

Inclusion Criteria:

• Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective

• Eastern Cooperative Oncology Group (ECOG) performance status
• Life expectancy greater than 3 months

• Adequate organ and marrow function

• Written informed consent

• Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study

• In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST

Exclusion Criteria:

• Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184

• Administration of an investigational drug within 30 days of the first dose of XL184

• Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment

• Known brain metastases

• Uncontrolled intercurrent illness

• Pregnancy or breastfeeding

• Known HIV positive

• Known allergy or hypersensitivity to any of the components of the XL184 formulation